Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review (Q28534465)

relapsing-remitting multiple sclerosis

30 June 2019

1 reference

29 October 2020

central nervous system

1 reference

murine-derived monoclonal antibodies

12 September 2019

1 reference

1 August 2020

1 reference

29 October 2020

1 reference

1 reference

4

Emmanuelle Waubant

Emmanuelle

Waubant

1 reference

20 October 2023

Tamara Castillo-Trivino

series ordinal

1

author given names

Tamara

author last names

Castillo-Trivino

1 reference

20 October 2023

Dejana Braithwaite

series ordinal

2

author given names

Dejana

author last names

Braithwaite

1 reference

20 October 2023

Peter Bacchetti

series ordinal

3

author given names

Peter

author last names

Bacchetti

1 reference

20 October 2023

language of work or name

English

0 references

publication date

2 July 2013

8 references

25 April 2019

30 June 2019

12 September 2019

27 September 2019

27 November 2019

13 December 2019

1 August 2020

29 October 2020

8 references

25 April 2019

30 June 2019

12 September 2019

27 September 2019

27 November 2019

13 December 2019

1 August 2020

29 October 2020

8

0 references

issue

7

0 references

page(s)

e66308

0 references

copyright license

Creative Commons Attribution 4.0 International

8 references

25 April 2019

30 June 2019

12 September 2019

27 September 2019

27 November 2019

13 December 2019

1 August 2020

on focus list of Wikimedia project

29 October 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

B-cells in multiple sclerosis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

B cells and antibodies in CNS demyelinating disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699597

Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions

2 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0066308

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0066308

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0066308

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0066308

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/23843952

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23843952

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23843952

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0066308

1 reference

1891679

ADS bibcode

2013PLoSO...866308C

0 references

1891679

1 reference

1 reference

1 reference